市場調査レポート

商品コード

1445533

HPV (ヒトパピローマウイルス) ワクチンの世界市場の評価：タイプ・適応症・合成方法・流通チャネル・地域別の機会および予測 (2017～2031年)

Human Papillomavirus Vaccine Market Assessment, By Type, By Disease Indication, By Method of Synthesis, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月07日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 246 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,420円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,532円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,285,432円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のHPV (ヒトパピローマウイルス) ワクチンの市場規模は、2024年から2031年の予測期間中にCAGR 8.99％を記録し、2023年の45億8,000万米ドルから、2031年には91億1,000万米ドルの規模に成長すると予測されています。

HPVワクチン接種の重要性に対する認識の高まり、子宮頸癌やHPV感染に関連するその他の疾患の有病率の上昇、各国政府による取り組みやワクチン接種プログラム、ワクチン開発における技術の進歩など、いくつかの要因が同市場を牽引しています。

世界の政府や医療機関は、HPVワクチン接種の利点に関する認識を高め、若い青少年に焦点を当てたワクチン接種キャンペーンを実施するために積極的な措置を講じています。その結果、HPVワクチンの需要は一貫して上昇しており、HPV感染や関連疾患と闘うための重要な武器としてワクチン接種が受け入れられつつあることを示しています。

さらに、ワクチン開発の技術的進歩により、有効性と安全性が改善された先進的なHPVワクチンが導入され、市場の拡大が後押しされています。HPVワクチンの世界市場は、製薬会社や研究機関による多額の投資の焦点であり続けています。その目的は、画期的なワクチン製剤を開発し、より多くの人々がHPVワクチン接種の恩恵を受けられるよう、アクセシビリティを高めることです。

子宮頸癌の高い有病率

HPVワクチンの世界市場は、子宮頸癌の有病率の影響を強く受けています。子宮頸癌は女性の4番目に罹患率の高い癌となっています。世界の子宮頸癌患者の58％以上がアジアで発生しており、アフリカで20％、欧州で10％、ラテンアメリカで10％発生しています。同様に、子宮頸癌による死亡は58％をアジアが占め、アフリカが22％、ラテンアメリカが9％、その他の地域がそれに続くと予測されています。子宮頸癌患者の18％は中国、21％はインドであり、死亡率は中国が17％、インド23％でした。

研究開発への投資の増加

ここ数年、HPVワクチンの世界市場におけるR&Dへの投資が顕著に増加しています。資金提供の急増は、HPV感染や関連疾患の予防においてワクチンが果たす重要な役割に対する認識の高まりを反映しています。HPVワクチンの技術、製剤、流通の進歩を推進するため、世界各国の政府、製薬会社、研究機関は、さまざまな目的で協力関係を結んでいます。

当レポートでは、世界のHPV (ヒトパピローマウイルス) ワクチンの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
タイプ別
- 2価
- 4価
- 9価
適応症別
- 子宮頸癌
- 肛門癌
- 外陰癌・膣癌
- 陰茎癌
- 中咽頭癌
- その他
合成方法別
- 核酸ベース
- ペプチドベース
- プロテインベース
- 細胞ベース
- 生ベクターワクチン
流通チャネル別
- 病院
- 小売薬局
- 政府機関
- 非政府機関
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア

第5章世界のHPV (ヒトパピローマウイルス) ワクチン市場の展望：地域別

北米
欧州
アジア太平洋
南米
中東・アフリカ

第6章市場マッピング

タイプ別
適応症別
合成方法別
流通チャネル別
地域別

第7章マクロ環境と産業構造

需要供給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (参入5社)
特許分析 (該当する場合)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

GlaxoSmithKline PLC.
Merck & Co., Inc.
Beijing Health Guard Biotechnology, Inc.
China National Biotec Group Company Limited
Shanghai Bovax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd
Xiamen Innovax Biotech Co., Ltd.
Serum Institute of India Pvt. Ltd.
Eyegene Inc.
Janssen Biotech, Inc.

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 3. Global Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 4. Global Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 5. Global Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 6. Global Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 7. Global Human Papillomavirus Vaccine Market Share (%), By Region, 2017-2031F
Figure 8. North America Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 10. North America Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 11. North America Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 12. North America Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 13. North America Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 14. North America Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
Figure 15. United States Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 17. United States Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 18. United States Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 19. United States Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 20. United States Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 21. Canada Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 23. Canada Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 24. Canada Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 25. Canada Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 26. Canada Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 27. Mexico Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 29. Mexico Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 30. Mexico Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 31. Mexico Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 32. Mexico Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 33. Europe Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 35. Europe Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 36. Europe Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 37. Europe Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 38. Europe Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 39. Europe Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
Figure 40. Germany Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 42. Germany Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 43. Germany Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 44. Germany Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 45. Germany Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 46. France Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 47. France Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 48. France Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 49. France Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 50. France Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 51. France Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 52. Italy Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 54. Italy Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 55. Italy Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 56. Italy Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 57. Italy Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 58. United Kingdom Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 60. United Kingdom Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 61. United Kingdom Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 62. United Kingdom Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 63. United Kingdom Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 64. Russia Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 66. Russia Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 67. Russia Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 68. Russia Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 69. Russia Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 70. Netherlands Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 72. Netherlands Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 73. Netherlands Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 74. Netherlands Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 75. Netherlands Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 76. Spain Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 78. Spain Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 79. Spain Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 80. Spain Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 81. Spain Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 82. Turkey Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 84. Turkey Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 85. Turkey Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 86. Turkey Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 87. Turkey Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 88. Poland Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 90. Poland Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 91. Poland Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 92. Poland Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 93. Poland Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 94. South America Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 96. South America Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 97. South America Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 98. South America Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 99. South America Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 100. South America Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
Figure 101. Brazil Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 103. Brazil Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 104. Brazil Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 105. Brazil Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 106. Brazil Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 107. Argentina Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 109. Argentina Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 110. Argentina Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 111. Argentina Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 112. Argentina Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 113. Asia-Pacific Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 115. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 116. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 117. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 118. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 119. Asia-Pacific Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
Figure 120. India Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 121. India Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 122. India Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 123. India Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 124. India Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 125. India Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 126. China Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 127. China Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 128. China Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 129. China Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 130. China Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 131. China Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 132. Japan Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 134. Japan Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 135. Japan Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 136. Japan Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 137. Japan Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 138. Australia Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 140. Australia Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 141. Australia Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 142. Australia Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 143. Australia Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 144. Vietnam Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 146. Vietnam Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 147. Vietnam Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 148. Vietnam Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 149. Vietnam Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 150. South Korea Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 152. South Korea Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 153. South Korea Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 154. South Korea Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 155. South Korea Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 156. Indonesia Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 158. Indonesia Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 159. Indonesia Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 160. Indonesia Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 161. Indonesia Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 162. Philippines Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 164. Philippines Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 165. Philippines Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 166. Philippines Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 167. Philippines Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 168. Middle East & Africa Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 170. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 171. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 172. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 173. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 174. Middle East & Africa Human Papillomavirus Vaccine Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 177. Saudi Arabia Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 178. Saudi Arabia Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 179. Saudi Arabia Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 180. Saudi Arabia Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 181. UAE Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 183. UAE Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 184. UAE Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 185. UAE Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 186. UAE Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 187. South Africa Human Papillomavirus Vaccine Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa Human Papillomavirus Vaccine Market, By Volume, In Thousand Units, 2017-2031F
Figure 189. South Africa Human Papillomavirus Vaccine Market Share (%), By Type, 2017-2031F
Figure 190. South Africa Human Papillomavirus Vaccine Market Share (%), By Disease Indication, 2017-2031F
Figure 191. South Africa Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, 2017-2031F
Figure 192. South Africa Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, 2017-2031F
Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By Method of Synthesis Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11082

Global human papillomavirus vaccine market size was valued at USD 4.58 billion in 2023 which is expected to reach USD 9.11 billion in 2031 with a CAGR of 8.99% for the forecast period between 2024 and 2031. Several factors are driving the global human papillomavirus vaccine market such as growing awareness about the importance of HPV vaccination, rising prevalence of cervical cancer and other diseases linked to HPV infection, initiatives, and vaccination programs launched by the governments, and technological advancements in vaccine development.

Governments and healthcare organizations across the globe have taken proactive steps to raise awareness about the advantages of HPV vaccination and execute vaccination campaigns, focusing on young adolescents. Consequently, the demand for HPV vaccines has consistently risen, showcasing the increasing acceptance of vaccination as a vital weapon in combatting HPV infections and related diseases.

Furthermore, the market's expansion has been bolstered by technological advancements in vaccine development, giving rise to the introduction of advanced HPV vaccines with improved efficacy and safety characteristics. The global human papillomavirus vaccine market remains a focal point for substantial investments from pharmaceutical companies and research institutions. Their objective is to develop groundbreaking vaccine formulations and enhance accessibility, ensuring that a larger population can benefit from HPV vaccination.

Nigeria incorporated the human papillomavirus (HPV) vaccine into its regular vaccination program in October 2023 to vaccinate 7.7 million girls. It is the highest number of HPV vaccinations given to patients in a single round in the African continent. The vaccine is very effective at preventing infection with HPV types 16 and 18, which are known to be the cause of at least 70% of cervical cancers, which will be given to girls between the ages of 9 and 14 in a single dosage.

High Prevalence of Cervical Cancer

The global human papillomavirus vaccine market is highly affected by the prevalence of cervical cancer. Worldwide, cervical cancer ranks as the fourth most prevalent cancer among women. More than 58% of cervical cancer cases worldwide were found in Asia, with 20% occurring in Africa, 10% in Europe, and 10% in Latin America. Similarly, it was predicted that Asia accounted for 58% of cervical cancer deaths, followed by Africa (22%), Latin America (9%), and other regions. China accounted for 18% of cervical cancer patients and India accounted for 21%, whereas mortality rates were 17% in China and 23% in India. The age-standardized incidence of cervical cancer was at its lowest in Western Asia, with 4.1 cases per 100,000 women-years.

Incidence rates were relatively low in Oceania, Northern America, and most regions of Europe, except for some countries in central and eastern Europe, such as Romania (22.6) and Bulgaria (18.0). Mortality rates showed a similar pattern to incidence, displaying significant variations across regions. Eastern Africa had the highest mortality rates at 28.6 deaths per 100,000 women years, while Western Europe reported the lowest mortality rates.

Increasing Investments in Research and Development

Over the past few years, there has been a notable increase in research and development investments in the global human papillomavirus vaccine market. The surge in funding reflects the growing recognition of the critical role these vaccines play in preventing HPV infections and associated diseases. To drive advancements in HPV vaccine technology, formulation, and distribution; governments, pharmaceutical companies, and research institutions worldwide have formed collaborations with different objectives.

The Gavi Board, in December 2022, approved the revitalization of the Alliance's HPV vaccination program, earmarking an investment of over USD 600 million by the end of 2025. With substantial funding, the Alliance has set a commendable objective of reaching more than 86 million girls by 2025 and preventing 1.4 million potential deaths from cervical cancer in the future.

Government Initiatives

Governments across the globe have acknowledged the importance of addressing the impact of cervical cancer and have initiated various initiatives to combat this virus. Initiatives taken by the government have helped in the growth of the global human papillomavirus vaccine market. Governments have implemented national cervical cancer screening programs, offering regular screening tests like pap smears or HPV testing, to detect pre-cancerous lesions in their early stages. These programs play a vital role in reducing the occurrence of cervical cancer by facilitating timely interventions. For instance, in the interim budget for 2024-2025, Union Finance Minister of India declared that the government intended to vaccinate all girls aged 9-14 against cervical cancer. It occurred more than a year after the vaccine's introduction under the Universal Vaccination Programme (UIP) was recommended by the National Technical Advisory Group on Immunization (NTAGI), the highest vaccination advisory body of the national government.

Increasing Demand for Bivalent Vaccine

Rising demand for bivalent vaccines has caused an increase in the growth of the global human papillomavirus vaccine market. The bivalent human papillomavirus (HPV) vaccine has become a pivotal weapon in the battle against cervical cancer and other HPV-related diseases. With its focus on targeting specific HPV strains responsible for a large proportion of cervical cancer cases, the vaccine has garnered considerable interest and recognition for its demonstrated efficacy and safety.

The HPV bivalent vaccine is administered to girls and young women aged 9 to 25. It is important to note that individuals can receive this vaccine even if they have previously tested positive for HPV or have had an abnormal pap smear in the past. In May 2022, China's National Medical Products Administration (NMPA) granted approval for a two-dose vaccine schedule of Cervarix, a bivalent vaccine developed by GlaxoSmithKline PLC, a British multinational pharmaceutical and biotechnology company. The approval was for the prevention of cervical cancer, cervical intraepithelial neoplasia, and adenocarcinoma in-situ linked to oncogenic Human Papillomavirus (HPV) types 16 and 18.

Growing Demand for Human Papillomavirus Vaccine for Cervical Cancer

In response to significant public health challenges, the development of HPV vaccines has emerged as a crucial preventive strategy against cervical cancer and other HPV-related illnesses, which has led to the growth of global human papillomavirus vaccine market. Their introduction of HPV vaccine has sparked significant interest in preventive healthcare, presenting a promising approach to alleviate the burden of cervical cancer and its impact. Through rigorous research and clinical trials, these vaccines have demonstrated their efficacy and safety, paving the way for their widespread incorporation into national immunization programs. Walvax Biotechnology, a Chinese drug developer, received approval to launch its recombinant bivalent human papillomavirus vaccine in China in March 2022. This vaccine has demonstrated efficacy in preventing cervical cancer caused by specific HPV strains, making it a significant milestone in the fight against human papillomavirus.

Asia-Pacific to Dominate the Market in Terms of Prevalence and Vaccination Drives

Cervical cancer is highly prevalent in Asian nations. Asia accounted for an estimated 58% of all cervical cancer cases worldwide. Several measures are being taken by governments in Asia-Pacific to address this problem. It is advised to receive the HPV vaccine as part of a comprehensive and well-coordinated plan to prevent HPV-related diseases, including cervical cancer. While India and Indonesia have implemented HPV, countries, such as Bhutan, Sri Lanka, Thailand, and Maldives have it on a national scale. HPV demonstration programs have been completed in Bangladesh and Nepal, and plans are in motion for a countrywide introduction. The introduction plans for Myanmar have been authorized. Crowell & Moring International formed the Asia-Pacific Women's Cancer Coalition in June 2023, partnering with Roche, TogetHER for Health, CAPED, and Jhpiego to increase awareness about the rise in breast and cervical cancer incidence in Asia-Pacific. To assist nations in reaching their national goals for cancer prevention and control, the coalition focuses on finding opportunities and filling up the gaps.

Future Market Scenario (2024 - 2031F)

The increased prevalence of HPV-related diseases, including cervical, anal, and oropharyngeal malignancies, is driving the demand for HPV vaccines globally.

Strategic approvals and activities to increase vaccine coverage are taking place in global human papillomavirus vaccine market.

In the global human papillomavirus vaccine market, major pharmaceutical companies are concentrating on developing new products and improving vaccination efficiency through research and development.

Cervical cancer is more prevalent in developing countries. Due to increasing urbanization, the prevalence of cervical cancer will increase leading to an increase in demand for HPV in developing countries coupled with awareness campaigns launched by governments.

Key Players Landscape and Outlook

Over the past few years, global human papillomavirus vaccine market has experienced a significant trend of mergers and collaborations among pharmaceutical companies and research institutions. These strategic partnerships have emerged as powerful drivers in advancing HPV vaccine development and distribution, with the shared goal of addressing the burden of HPV infections and associated diseases on a worldwide scale. The increasing demand for HPV vaccines, fueled by the growing awareness of their preventive benefits against cervical cancer and other HPV-related illnesses, has spurred key industry players to unite their efforts. Through mergers and collaborations, these companies combine their resources, expertise, and research capabilities to accelerate vaccine development, enhance formulations, and extend their reach in global human papillomavirus vaccine market.

For instance, in December 2022, NusaGard, a human papillomavirus (HPV) vaccination, was launched by Bio Farma Induk Holding BUMN Pharmacy in partnership with Merck Sharp & Dohme (MSD) and its subsidiaries, Kimia Farma and Indofarma.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Human Papillomavirus Vaccine Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2. By Type
- 4.2.1. Bivalent
- 4.2.2. Quadrivalent
- 4.2.3. Nonavalent
4.3. By Disease indication
- 4.3.1. Cervical cancer
- 4.3.2. Anal cancer
- 4.3.3. Vulvar & Vaginal cancer
- 4.3.4. Penile cancer
- 4.3.5. Oropharyngeal cancer
- 4.3.6. Others
4.4. By Method of Synthesis
- 4.4.1. Nucleic acid-based
  - 4.4.1.1. DNA
  - 4.4.1.2. mRNA
- 4.4.2. Peptide-based
- 4.4.3. Protein-based
- 4.4.4. Cell-based
- 4.4.5. Live vector vaccine
4.5. By Distribution Channel
- 4.5.1. Hospital
- 4.5.2. Retail Pharmacy
- 4.5.3. Government Organizations
- 4.5.4. Non-government Organizations
4.6. By Region
- 4.6.1. North America
- 4.6.2. Europe
- 4.6.3. South America
- 4.6.4. Asia-Pacific
- 4.6.5. Middle East and Africa
4.7. By Company Market Share (%), 2023

5. Global Human Papillomavirus Vaccine Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. By Value
  - 5.1.1.2. By Volume
- 5.1.2. By Type
  - 5.1.2.1. Bivalent
  - 5.1.2.2. Quadrivalent
  - 5.1.2.3. Nonavalent
- 5.1.3. By Disease indication
  - 5.1.3.1. Cervical cancer
  - 5.1.3.2. Anal cancer
  - 5.1.3.3. Vulvar and Vaginal Cancer
  - 5.1.3.4. Penile Cancer
  - 5.1.3.5. Oropharyngeal Cancer
  - 5.1.3.6. Others
- 5.1.4. By Method of Synthesis
  - 5.1.4.1. Nucleic acid-based
  - 5.1.4.1.1. DNA
  - 5.1.4.1.2. mRNA
  - 5.1.4.2. Peptide-based
  - 5.1.4.3. Protein-based
  - 5.1.4.4. Cell-based
  - 5.1.4.5. Live vector vaccine
- 5.1.5. By Distribution Channel
  - 5.1.5.1. Hospital
  - 5.1.5.2. Retail Pharmacy
  - 5.1.5.3. Government Organizations
  - 5.1.5.4. Non-government Organizations
- 5.1.6. United States*
  - 5.1.6.1. Market Size & Forecast
  - 5.1.6.1.1. By Value
  - 5.1.6.1.2. By Volume
  - 5.1.6.2. By Type
  - 5.1.6.2.1. Bivalent
  - 5.1.6.2.2. Quadrivalent
  - 5.1.6.2.3. Nonavalent
  - 5.1.6.3. By Disease Indication
  - 5.1.6.3.1. Cervical cancer
  - 5.1.6.3.2. Anal cancer
  - 5.1.6.3.3. Vulvar & Vaginal cancer
  - 5.1.6.3.4. Penile cancer
  - 5.1.6.3.5. Oropharyngeal Cancer
  - 5.1.6.3.6. Others
  - 5.1.6.4. By Method of synthesis
  - 5.1.6.4.1. Nucleic acid-based
  - 5.1.6.4.1.1. DNA
  - 5.1.6.4.1.2. mRNA
  - 5.1.6.4.2. Peptide-based
  - 5.1.6.4.3. Protein-based
  - 5.1.6.4.4. Cell-based
  - 5.1.6.4.5. Live vector vaccine
  - 5.1.6.5. By Distribution Channel
  - 5.1.6.5.1. Hospital
  - 5.1.6.5.2. Retail Pharmacy
  - 5.1.6.5.3. Government Organizations
  - 5.1.6.5.4. Non-government Organizations
- 5.1.7. Canada
- 5.1.8. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. South America
- 5.3.1. Brazil
- 5.3.2. Argentina
5.4. Asia Pacific
- 5.4.1. India
- 5.4.2. China
- 5.4.3. Japan
- 5.4.4. Australia
- 5.4.5. Vietnam
- 5.4.6. South Korea
- 5.4.7. Indonesia
- 5.4.8. Philippines
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Type
6.2. By Disease indication
6.3. By Method of synthesis
6.4. By Distribution channel
6.5. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. GlaxoSmithKline PLC.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. Merck & Co., Inc.
13.3. Beijing Health Guard Biotechnology, Inc.
13.4. China National Biotec Group Company Limited
13.5. Shanghai Bovax Biotechnology Co., Ltd.
13.6. Walvax Biotechnology Co., Ltd
13.7. Xiamen Innovax Biotech Co., Ltd.
13.8. Serum Institute of India Pvt. Ltd.
13.9. Eyegene Inc.
13.10. Janssen Biotech, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

HPV (ヒトパピローマウイルス) ワクチンの世界市場の評価：タイプ・適応症・合成方法・流通チャネル・地域別の機会および予測 (2017～2031年)

Human Papillomavirus Vaccine Market Assessment, By Type, By Disease Indication, By Method of Synthesis, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のHPV (ヒトパピローマウイルス) ワクチン市場の展望

第5章世界のHPV (ヒトパピローマウイルス) ワクチン市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Human Papillomavirus Vaccine Market Outlook, 2017-2031F

5. Global Human Papillomavirus Vaccine Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

HPV (ヒトパピローマウイルス) ワクチンの世界市場の評価：タイプ・適応症・合成方法・流通チャネル・地域別の機会および予測 (2017～2031年)

Human Papillomavirus Vaccine Market Assessment, By Type, By Disease Indication, By Method of Synthesis, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のHPV (ヒトパピローマウイルス) ワクチン市場の展望

第5章 世界のHPV (ヒトパピローマウイルス) ワクチン市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Human Papillomavirus Vaccine Market Outlook, 2017-2031F

5. Global Human Papillomavirus Vaccine Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のHPV (ヒトパピローマウイルス) ワクチン市場の展望

第5章世界のHPV (ヒトパピローマウイルス) ワクチン市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項